The proposed DLS offered a non-invasive and accurate approach for assessing PD-L1 expression in patients with HNSCC and effectively stratified HNSCC patients to benefit from immunotherapy based on PFS. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.